ArticleOncotarget2018
Development of novel miR-129 mimics with enhanced efficacy to eliminate chemoresistant colon cancer stem cells.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- GDF15 promotes 5-Fluorouracil and Oxaliplatin resistance by promoting stem cell-like phenotype in colorectal cancer.British journal of cancer · 2026Article
- The Promise and Pursuit of MicroRNAs for Cancer Treatment.Biomolecules · 2026Review
- Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma.Molecular therapy. Oncology · 2024Article
- Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer.Molecular therapy oncolytics · 2023Article
- Recent advances microRNAs and metabolic reprogramming in colorectal cancer research.Frontiers in oncology · 2023Review
- Analysis of MicroRNAs in Ferroptosis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Role of microRNA-129 in cancer and non-cancerous diseases (Review).Experimental and therapeutic medicine · 2021Review
- The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer.Cancers · 2021Review
- MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development.International journal of molecular sciences · 2021Review
- Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers.Cancers · 2020Article
- Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.Molecular therapy. Nucleic acids · 2020Article
- Development of microRNA-based therapy for pancreatic cancer.Journal of pancreatology · 2019Article
- MiR-4319 suppresses colorectal cancer progression by targeting ABTB1.United European gastroenterology journal · 2019Article
- Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis.Open biology · 2019Review
- MiR-566 mediates cell migration and invasion in colon cancer cells by direct targeting ofCancer cell international · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundResistance to 5-Fluorouracil (5-FU) based chemotherapy is the major reason for failure of treating patients with advanced colorectal cancer. MATERIALS AND
methodsIn this study, we developed a novel miR-129 mimic with potent efficacy in eliminating resistant colon cancer stem cells both
resultsMimic-1 is a strong therapeutic candidate with a number of unique features. Mimic-1 can be delivered to cancer cells without any transfection reagents (e.g. lipids, viral vector, nanoparticles). Mimic-1 is more potent at inhibiting cell proliferation and inducing cell cycle arrest at G1 phase than native miR-129 and the other mimics tested, while retaining target specificity. Mimic-1 prevents colon cancer metastasis
conclusionThis represents a significant advancement in the development of a nontoxic and highly potent miRNA based cancer therapeutics and establishes a foundation for further developing Mimic-1 as a novel anti-cancer therapeutic for treating colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.